CRBP · Corbus Pharmaceuticals Holdings Inc
United States · RS rating 4 · As of 2026-10-14
| Price | 4.41 USD |
|---|---|
| 1-day change | -7.7% |
| RS rating (overall / 1M / 3M / 12M) | 4 / 4 / 5 / 8 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 21 / 14 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +34.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +77.2% |
| Market cap (USD) | $181.3M |